Real-world analysis of Provenge in prostate cancer shows reduction in risk of death and prolonged OS.- Dendreon Pharmaceuticals

Dendreon Pharmaceuticals announced publication of an analysis examining real-world survival outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with Provenge (sipuleucel-T) and commonly prescribed oral treatments. The analysis of Medicare claims data from more than 6,000 fee-for-service beneficiaries showed that the addition of Provenge to either Zytiga (abiraterone acetate) or Xtandi (enzalutamide), at any point in a patient’s mCRPC treatment regimen, reduced the risk of death by 41% and prolonged median overall survival (OS) by 14.5 months. The analysis compared first-line treatment with Provenge versus first-line treatment with oral agents, including patients who received Provenge in the second-line or later, as well as any-line Provenge versus any-line oral agents (without Provenge), from 2013 to 2017. Findings were published online in the journal Advances in Therapy. Data showed that in Medicare beneficiaries treated with approved mCRPC treatments, the median OS was significantly longer among men who also were treated with Provenge (35.2 months vs. 20.7 months in the any-line cohort and 34.9 months vs. 21.0 months in the first-line cohort). Men who received Provenge as a first-line treatment had a 44% reduction in the risk of death at three years compared to those receiving oral agents as first-line treatment (adjusted hazard ratio, 0.56; 95% CI, 0.494-0.627). Similar results were observed in the any-line cohort, where there was a 41% decrease in the risk of death at three years in patients receiving Provenge versus those receiving an oral agent (without Provenge) (adjusted hazard ratio, 0.59; 95% CI, 0.527-0.651). While safety was not a focus of this analysis, first-line use of Provenge resulted in fewer emergency department (ED) visits in the first year compared to oral treatments.